| Value | ₹28.47 Cr |
|---|
BSE filing, NSE: KPL. Summary written from the filing by ALFA Finder's alert engine.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,701.75
- Market cap
- ₹3,841 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.4×Sector 46.1×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Other debt & borrowing announcements
All →QGO Finance Debt & Borrowing: ₹1 Cr
QGO Finance Ltd has redeemed 100 unlisted non-convertible debentures, with a total value of Rs. 1 Crore, including the principal and applicable interest.
- Value
- ₹1.00 Cr
Capri Global Capital Debt & Borrowing: ₹1.42 Cr
Capri Global paid interest on four listed NCD series ahead of their due dates, totalling Rs.1.42 Crore. The Reg 57 certificate reports no payment changes or delays.
- Value
- ₹1.42 Cr
Ugro Capital Debt & Borrowing: ₹2.99 Cr
Ugro Capital paid Rs 2.99 Crore in interest on two NCD series on 29 October 2026. Payments were made a day before the 30 October due date.
- Value
- ₹2.99 Cr
Time Technoplast Debt & Borrowing: ₹50 Cr
Time Technoplast redeemed its Rs.50 Crore commercial paper in full on maturity on 29 October 2026. The redemption completes servicing of this short-term debt instrument.
- Value
- ₹50.00 Cr
Samvardhana Motherson International Debt & Borrowing: ₹834.8 Cr
Samvardhana Motherson issued a corporate guarantee for a EUR 75 million BNP Paribas term facility of subsidiary MGI B.V. Liability capped at ₹834.75 Crore.
- Value
- ₹834.8 Cr
- Execution
- Guarantee valid up to February 28, 2032
Electrotherm (India) Debt & Borrowing: ₹59.81 Cr
Electrotherm disclosed a Rs 59.81 Crore default on bank loans as at 30 September 2026. The loans were assigned to an ARC under a settlement.
- Value
- ₹59.81 Cr